Ocugen Inc Stock Price, News & Analysis

Ocugen Receives Orphan Drug Designation from FDA for OCU410ST aimed at treating ABCA4-associated retinopathies, including Stargardt disease, Retinitis Pigmentosa 19, and Cone-Rod Dystrophy 3. This designation highlights the potential of OCU410ST to address a significant gap in treatment options for the approximately 44,000 patients in the U.S. affected by these conditions. The gene therapy utilizes an AAV delivery platform to administer the RORA gene, which plays a crucial role in retinal health. Ocugen plans to submit an IND application in Q2 2023 to start a Phase 1/2 clinical trial, furthering their commitment to innovative treatments in rare retinal diseases.

Ocugen, a biotechnology firm focused on innovative therapies, announced that its CEO, Dr. Shankar Musunuri, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on May 2, 2023, from 11 a.m. to 11:30 a.m. EDT. The event will be held at the Nasdaq Market Site in New York City.

Dr. Musunuri will discuss the company's advancements, including positive results from the ongoing OCU400 Phase 1/2 trial, and outline expected milestones. Investors can also schedule one-on-one meetings with Ocugen's leadership team during the conference.

A live video webcast of the discussion will be available on Ocugen's investor site.

MALVERN, Pa., April 20, 2023 (GLOBE NEWSWIRE) -- Ocugen (NASDAQ: OCGN) is set to present its innovative modifier gene therapy platform at the ARVO 2023 Annual Meeting from April 23-27, 2023. The therapies include OCU400, targeting retinitis pigmentosa and Leber congenital amaurosis, OCU410 for dry age-related macular degeneration (dry AMD), and OCU410ST for Stargardt disease, along with biomolecule OCU200 for diabetic macular edema (DME). Following positive Phase 1/2 trial results for OCU400, Ocugen aims to share its advancements in treating complex retinal diseases affecting millions globally. Key presentations by Ocugen team members are scheduled throughout the conference, providing crucial insights into their ongoing research and development efforts.

Ocugen, a biotechnology company, announced positive preliminary results from its Phase 1/2 clinical trial for OCU400, aimed at treating retinitis pigmentosa (RP) and Leber Congenital Amaurosis (LCA) associated with specific genetic mutations. The trial enrolled 18 RP subjects and demonstrated a favorable safety profile alongside visual improvements. Key data includes:

• 71.4% of treated eyes experienced at least 1 Lux luminance level improvement in mobility tests.
• 66.7% of low dose cohort eyes showed at least 2 Lux improvement at the 9-month follow-up.
• 100% of treated eyes had stable or improved mobility testing scores.

Ocugen believes these findings validate its modifier gene therapy platform and plans to pursue further long-term data collection and potential Phase 3 trials.

Ocugen Announces Investor Event for OCU400 Data

Ocugen, a biotechnology firm focused on gene and cell therapies, will host an Investor and Analyst Event on April 14, 2023, at 8 a.m. ET. The event aims to share preliminary safety and efficacy data from its ongoing Phase 1/2 trial of OCU400, targeting retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA). Members of the Ocugen leadership team, including CEO Shankar Musunuri and Chief Scientific Officer Arun Upadhyay, will present findings alongside noted experts in the field. Interested parties can join via a webcast or dial-in numbers. A replay will be accessible for 45 days post-event. Ocugen is committed to pioneering innovative therapies for severe retinal diseases.

Ocugen, a biotechnology firm focused on gene therapies, announced that Chief Scientific Officer Dr. Arun Upadhyay will present at the World Vaccine Congress in Washington D.C. on April 5, 2023. He will showcase Ocugen's innovative inhaled vaccine technology aimed at combating COVID-19 and influenza, addressing current vaccine limitations. The company is advancing multiple inhaled vaccine candidates, including OCU500 for COVID-19 and OCU510 for seasonal flu, targeting a significant market with over 170 million doses in the USA alone for the 2022-2023 flu season. This cutting-edge approach aims to enhance mucosal immunity and reduce transmission.